Literature DB >> 33841627

The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2.

Shilei Wang1, Jinlei Ye1, Zhichao Kang1, Hongmei Peng2, Vienna Mackey3, Lichun Sun1,3,4.   

Abstract

Coronavirus SARS-CoV-2 is a novel coronavirus and the seventh that can infect human beings and result in severe and acute respiratory syndrome and deaths. Currently, the world is undergoing a global health emergency due to the SARS-CoV-2 pandemic. As of May 18, SARS-CoV-2 has spread to over two hundred countries and infected more than 4.8 million people, resulting in over 300,000 deaths since the first case of a novel pneumonia (COVID-19) patient was discovered in Wuhan, China at the end of December 2019. Currently, there are no effective and/or approved targeting drugs for it though various supportive therapy drugs such as small molecule drugs, vaccines, antibodies and even Chinese herb medicines have been used in the treatment of the first-line patients. However, certain drugs such as remdesivir and S416 are under clinical investigation and may become therapeutic drugs. In this article, we review and discuss SARS-CoV-2, its person-to-person transmission, genomics and proteomics, and the potential for drug development. AJTR
Copyright © 2021.

Entities:  

Keywords:  S416; SARS-CoV-2; coronavirus; epidemiology; genomics; outbreak; proteomics; remdesivir

Year:  2021        PMID: 33841627      PMCID: PMC8014381     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  47 in total

1.  Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.

Authors:  Jean-Michel Molina; Kathleen Squires; Paul E Sax; Pedro Cahn; Johan Lombaard; Edwin DeJesus; Ming-Tain Lai; Anthony Rodgers; Lisa Lupinacci; Sushma Kumar; Peter Sklar; George J Hanna; Carey Hwang; Elizabeth Anne Martin
Journal:  Lancet HIV       Date:  2019-11-15       Impact factor: 12.767

2.  SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes.

Authors:  Chong-Shan Shi; Neel R Nabar; Ning-Na Huang; John H Kehrl
Journal:  Cell Death Discov       Date:  2019-06-05

3.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

4.  Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.

Authors:  Syed Faraz Ahmed; Ahmed A Quadeer; Matthew R McKay
Journal:  Viruses       Date:  2020-02-25       Impact factor: 5.048

5.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

6.  Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine.

Authors:  Fan Luo; Fan-Lu Liao; Hui Wang; Hong-Bin Tang; Zhan-Qiu Yang; Wei Hou
Journal:  Virol Sin       Date:  2018-03-14       Impact factor: 4.327

7.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.

Authors:  Huijun Chen; Juanjuan Guo; Chen Wang; Fan Luo; Xuechen Yu; Wei Zhang; Jiafu Li; Dongchi Zhao; Dan Xu; Qing Gong; Jing Liao; Huixia Yang; Wei Hou; Yuanzhen Zhang
Journal:  Lancet       Date:  2020-02-12       Impact factor: 79.321

8.  Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak.

Authors:  Shi Zhao; Qianyin Lin; Jinjun Ran; Salihu S Musa; Guangpu Yang; Weiming Wang; Yijun Lou; Daozhou Gao; Lin Yang; Daihai He; Maggie H Wang
Journal:  Int J Infect Dis       Date:  2020-01-30       Impact factor: 3.623

9.  Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.

Authors:  Feng-Cai Zhu; Yu-Hua Li; Xu-Hua Guan; Li-Hua Hou; Wen-Juan Wang; Jing-Xin Li; Shi-Po Wu; Bu-Sen Wang; Zhao Wang; Lei Wang; Si-Yue Jia; Hu-Dachuan Jiang; Ling Wang; Tao Jiang; Yi Hu; Jin-Bo Gou; Sha-Bei Xu; Jun-Jie Xu; Xue-Wen Wang; Wei Wang; Wei Chen
Journal:  Lancet       Date:  2020-05-22       Impact factor: 202.731

Review 10.  World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).

Authors:  Catrin Sohrabi; Zaid Alsafi; Niamh O'Neill; Mehdi Khan; Ahmed Kerwan; Ahmed Al-Jabir; Christos Iosifidis; Riaz Agha
Journal:  Int J Surg       Date:  2020-02-26       Impact factor: 6.071

View more
  1 in total

Review 1.  Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19).

Authors:  Banlambhabok Khongthaw; Kanika Dulta; Pankaj Kumar Chauhan; Vinod Kumar; Joshua O Ighalo
Journal:  Inflammopharmacology       Date:  2022-09-01       Impact factor: 5.093

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.